Taysha Gene Therapies, Inc. Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

Rank in Stocks #6466
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and... Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Share Price
$4.10
Last synced: 2026-11-13
Market Cap
$1.67B
Change (1 day)
-2.61%
Change (1 year)
2.76%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Taysha Gene Therapies, Inc. (TSHA)

Category

Healthcare
Operating Margin for Taysha Gene Therapies, Inc. (TSHA)
Operating Margin as of November 2026 TTM: -2,935.41%
According to Taysha Gene Therapies, Inc.'s latest financial reports, its current operating margin (TTM) is -2,935.41%. At the end of 2025 the company had an operating margin of -1,130.65%.
Operating Margin history for Taysha Gene Therapies, Inc. from 2019 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -2,935.41% 159.62%
2025 -1,130.65% 3.02%
2024 -1,097.55% 134.10%
2023 -468.83% -90.69%
2022 -5,037.05% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -99.93%
US
33.87% -100.01%
US
-116.04% -99.96%
US
25.57% -100.01%
AU
31.23% -100.01%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Taysha Gene Therapies, Inc.'s operating margin

What is Taysha Gene Therapies, Inc.'s operating margin?

Taysha Gene Therapies, Inc.'s operating margin is -2,935.41%, as of Nov 2026.

What was Taysha Gene Therapies, Inc.'s operating margin in 2025?

In 2025, Taysha Gene Therapies, Inc.'s operating margin was -1,130.65%, compared with -1,097.55% in 2024.

How has Taysha Gene Therapies, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Taysha Gene Therapies, Inc.'s operating margin was highest in 2021 (0.00%) and lowest in 2022 (-5,037.05%).

How does Taysha Gene Therapies, Inc.'s operating margin compare with similar companies?

Taysha Gene Therapies, Inc.'s operating margin (-2,935.41%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.